ACTIVELLA (estradiol/norethindrone acetate) by Amneal Pharms is estrogen receptor agonists [moa]. First approved in 1998.
Drug data last refreshed 22h ago · AI intelligence enriched 1mo ago
ACTIVELLA is an oral tablet combining estradiol and norethindrone acetate, estrogen receptor agonists used in hormone replacement therapy. It is indicated for menopausal symptom relief and osteoporosis prevention in postmenopausal women. The combination works by supplementing endogenous estrogen levels to alleviate vasomotor and genitourinary symptoms.
Limited growth trajectory with LOE approaching signals consolidation roles; expect smaller commercial teams focused on retention and compliance.
Estrogen Receptor Agonists
Estrogen
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women
Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (Replicate Study)
Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women
Estradiol/Norethindrone Acetate Tablets, 1/0.5 mg Under Fasting Conditions
Estradiol/Norethindrone Acetate Tablets, 1/0.5 mg Under Fed Conditions
Worked on ACTIVELLA at Amneal Pharms? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moACTIVELLA represents a mature, declining-revenue product with minimal new opportunity; career prospects center on defensive commercial roles and regulatory management. Employment growth is limited, with roles concentrated in maintaining market position and managing LOE transition rather than driving expansion.